Advertisement

Primary Plasma Cell Leukemia: A Retrospective Study of a Rare Disease From Tertiary Cancer Centre From India

  • Neha Yadav
  • Mukul Aggarwal
  • Pallavi Mehta
  • Jyotsna Kapoor
  • Shinto Francis Thekkudan
  • Pragya Bhandari
  • Priyanka Soni
  • Rayaz Ahmed
  • Dinesh Bhurani
  • Narendra AgrawalEmail author
Original Article
  • 11 Downloads

Abstract

Plasma cell leukemia (PCL) is an aggressive rare leukemic variant of multiple myeloma (MM). We aim to present 4 years data on clinical profile and treatment outcomes of Primary PCL (PPCL) patients treated at tertiary care cancer centre from Northern India. To analyse response and safety profile of a PPCL with or without stem cell transplantation. Retrospectively reviewed and analysed PPCL patient’s data at our centre from January-2013 to June-2017. Total 11 PPCL patients diagnosed among 240 MM patients during study period. Eight were males. Only 10 patients were started on treatment. Four (n = 4/10) patients underwent stem cell transplantation. Overall response rate was 70% (n = 7). Eleven culture positive bacterial infections (bloodstream = 2, urinary tract = 3; pulmonary = 6) were recorded. Four patients had fungal infections. One patient had Herpes Zoster infection. Relapse rate of entire cohort was 50% (n = 5). Median PFS and OS of entire cohort was 11 months (95% confidence interval 6.3–15.6) and 21 months (95% C.I. 1–49.8) respectively. The estimated PFS and OS at 1 year of transplanted versus nontransplanted patients were 71% + 24% versus 0% (P = 0.96) and 71% + 24% versus 15% + 19% (P = 0.234) respectively. Treatment with PIs + IMAs followed by transplants (single/double) might improve depth and duration of remission and OS. Patients should be treated with indefinite maintenance therapy to control disease.

Keywords

Primary plasma cell leukemia Stem cell transplantation Multiple myeloma Overall survival 

Notes

Acknowledgements

We would like to acknowledge an entire team of hemato-oncology and bone marrow transplant unit, Rajiv Gandhi Cancer Institute & Research Centre for their continuous support for retrieving records of eligible patients.

Compliance with Ethical Standards

Conflict of interest

All authors have declare that they have no conflict of interest.

Human and Animal Rights

All procedures performed in study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by our Institutional Review Board (IRB).

Informed Consent

This is a retrospective study hence for this type of study formal consent is not required. IRB waived off the need to take consent for the study.

References

  1. 1.
    Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DF et al (2013) International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:780–791CrossRefGoogle Scholar
  2. 2.
    Pasqualethi P, Festuccia V, Collacciani A, Acitelli P, Casale R (1996) Plasma cell leukemia, a report on 11 cases and review of the literature. Panminerra Med. 38:179–184Google Scholar
  3. 3.
    Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R (1994) Plasma cell leukemia. Br J Hematol 88:754–759CrossRefGoogle Scholar
  4. 4.
    Kim SJ, Kim J, Cho Y, Seo BK, Kim BS (2007) Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol 37:382–384CrossRefGoogle Scholar
  5. 5.
    Bladé J, Kyle RA (1999) Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 13:1259–1272CrossRefGoogle Scholar
  6. 6.
    Costello R, Sainty D, Bouabdallah R, Fermand JP, Delmer A, Divine M et al (2001) Primary plasma cell leukaemia: a report of 18 cases. Leuk Res 25:103–107CrossRefGoogle Scholar
  7. 7.
    Majumdar N, Kumar R, Anand M, Kalita D, Ghara N, Chopra A et al (2009) Plasma cell leukemia-a study of 28 cases from India. Hematology. 14:198–203CrossRefGoogle Scholar
  8. 8.
    Naseem S, Kaur S, Gupta R, Kashyap R, Nityanand S (2012) Plasma cell leukemia: case series from a tertiary center with review of literature. Indian J Hematol Blood Transfus 28:10–14CrossRefGoogle Scholar
  9. 9.
    Kar R, Priyadarshini SG, Niraimathi M, Basu D, Badhe BA (2012) Clinico-pathological spectrum of primary plasma cell leukemia diagnosed at a tertiary care centre in South India over 5 year period. Indian J Hematol Blood Transfus 28:170–174CrossRefGoogle Scholar
  10. 10.
    International Myeloma Working (IMW) (http://imwg.myeloma.org/)
  11. 11.
    Sher T, Miller KC, Deeb G et al (2010) Plasma Cell leukemia and other aggressive plasma cell malignancies. Br J Haemtol 150:418–427CrossRefGoogle Scholar
  12. 12.
    Albarracin F, Fonseca R (2011) Plasma cell leukemia. Blood Rev 25:107–112CrossRefGoogle Scholar
  13. 13.
    Musto P, Pagano L, Petrucci MT et al (2012) Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 82(2):141–149CrossRefGoogle Scholar
  14. 14.
    Pagano L, Valentini CG, De Stefano V, Venditti A, Visnaie G, Petrucci et al (2011) Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 22:1628–1635CrossRefGoogle Scholar
  15. 15.
    Musto P, D’Auria F, Petrucci MT, Levi A, Cascavilla N, Falcone A et al. (2011) A: final results of a phase II study evaluating lenalidomide in combination with low dose dexamethasone as first line therapy for primary plasma cell leukemia. Blood (ASH Annual Meeting Abstracts). p 118 (Abstract 2925)Google Scholar
  16. 16.
    Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D’Arena G et al (2007) Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 109:2285–2290CrossRefGoogle Scholar
  17. 17.
    D’Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G et al (2012) Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 23:1499–1502CrossRefGoogle Scholar
  18. 18.
    Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S (2008) Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol 25(2):154–160CrossRefGoogle Scholar
  19. 19.
    García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, Fernández-Calvo J, Sanz MA, Pérez-Simón JA, Rasillo A, Miguel JF (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93(3):1032–1037CrossRefGoogle Scholar
  20. 20.
    Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole D, Zhang MJ, Li P et al (2012) Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 26:1091–1097CrossRefGoogle Scholar
  21. 21.
    Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D et al (2010) Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 95:804–809CrossRefGoogle Scholar
  22. 22.
    Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C et al (2016) Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du Myélome. J ClinOncol 34:2125–2132CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  • Neha Yadav
    • 1
  • Mukul Aggarwal
    • 1
  • Pallavi Mehta
    • 1
  • Jyotsna Kapoor
    • 1
  • Shinto Francis Thekkudan
    • 1
  • Pragya Bhandari
    • 1
  • Priyanka Soni
    • 1
  • Rayaz Ahmed
    • 1
  • Dinesh Bhurani
    • 1
  • Narendra Agrawal
    • 1
    Email author
  1. 1.Department of Hemato-OncologyRajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research CentreNew DelhiIndia

Personalised recommendations